



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Institute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/540,443
Filing Date	06/22/2005
First Named Inventor	Robin L. Polt
Art Unit	
Examiner Name	
Attorney Docket Number	920214.00005

Sheet 1 of 2

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
E G		US- 4,407,794	10/04/1983	Roques et al.	
		US- 5,767,254	06/16/1998	Polt	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	⁶

Examiner
Signature

Date
Considered

11/8/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Best Available Copy

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/540,443
Filing Date	06/22/2005
First Named Inventor	Robin L. Polt
Art Unit	
Examiner Name	
Attorney Docket Number	920214.00005

Sheet 2 of 2

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
6		Bilsky, E.J., et al., "Enkephalin Glycopeptide Analogues Produce Analgesia with Reduced Dependence Liability, Journal of Medicinal Chemistry 43:2586-2590 (2000)	
		Egleton, R.D., et al., "Improved bioavailability to the brain of glycosylated Met-enkephalin analogs," Brain Research 881:37-46 (2000)	
		Egleton, R.D., et al., "Improved Blood-Brain Barrier Penetration and Enhanced Analgesia of an Opioid Peptide by Glycosylation," The Journal of Pharmacology and Experimental Therapeutics 290:667-672 (2004)	
		Elmagbari, N., et al., "Antinociceptive Structure Activity Studies With Novel Opioid Glycopeptides," FASEB J. Vol. 15:A915 (2001) Annual Mtg. of the Federation of American Soc. for Exper. Biol. on Exper. Biol. 2001, Orlando FL Abstract 711	
		Horvat, S., et al., "A New Utility of O-Glycosylpseudoureas for Synthesis of Glucopeptides and (1-6)-Disaccharides," Synthesis 3:209-211 (1986)	
		Mitchell, S.A., et al., "Solid-Phase Synthesis of O-Linked Glycopeptide Analogues of Enkephalin," J. Org. Chem. 66:2327-2342 (2001)	
		Palian, M.M., et al., "Glycopeptide-membrane Interactions: Glycosyl Enkephalin Analogues Adopt Turn Conformations by NMR and CD in Amphipathic Media," J. Am. Chem. Soc. 125:5823-5831 (2003)	
		Polt, R., et al., "Glycopeptide enkephalin analogues produce analgesia in mice: Evidence for penetration of the blood-brain barrier," Proc. Natl. Acad. Sci. USA 91:7114-7118 (1994)	
		Polt, R., et al., "Glycosylated Enkephalins Penetrate the Blood-Brain Barrier Adsorptive Endocytosis—Analgesia Superior to Morphine," Abstract 225th ACS Nat'l Meeting, New Orleans, LA 2003 Abstract 256	

Examiner Signature		Date Considered	11/8/06
--------------------	---	-----------------	---------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Best Available Copy